David R Westhead
Overview
Explore the profile of David R Westhead including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
86
Citations
2296
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Willis L, Trayton I, Saunders J, Bruque M, Davis Birch W, Westhead D, et al.
Mol Pharm
. 2024 Dec;
22(1):181-195.
PMID: 39681988
A framework for the rational selection of a minimal suite of nondegenerate developability assays (DAs) that maximize insight into candidate developability or storage stability is lacking. To address this, we...
2.
Fife C, Williams J, James F, Gregory S, Andreou T, Sunderland A, et al.
J Immunother Cancer
. 2024 Nov;
12(11).
PMID: 39551601
Brain metastases (BrM) affect up to 60% of patients with metastatic melanoma and are associated with poor prognosis. While combined immune checkpoint blockade of programmed death-1 (PD-1) and cytotoxic T-lymphocyte-associated...
3.
Tanner G, Barrow R, Ajaib S, Al-Jabri M, Ahmed N, Pollock S, et al.
Genome Biol
. 2024 Feb;
25(1):45.
PMID: 38326875
Background: Glioblastoma (GBM) brain tumors lacking IDH1 mutations (IDHwt) have the worst prognosis of all brain neoplasms. Patients receive surgery and chemoradiotherapy but tumors almost always fatally recur. Results: Using...
4.
Zhang C, Stelloo E, Barrans S, Cucco F, Jiang D, Tzioni M, et al.
Leukemia
. 2024 Jan;
38(3):621-629.
PMID: 38184753
MYC translocation occurs in 8-14% of diffuse large B-cell lymphoma (DLBCL), and may concur with BCL2 and/or BCL6 translocation, known as double-hit (DH) or triple-hit (TH). DLBCL-MYC/BCL2-DH/TH are largely germinal...
5.
Hayward C, Batty J, Westhead D, Johnson O, Gale C, Wu J, et al.
EBioMedicine
. 2023 Sep;
96:104792.
PMID: 37741008
Background: Knowledge of post-myocardial infarction (MI) disease risk to date is limited-yet the number of survivors of MI has increased dramatically in recent decades. We investigated temporally ordered sequences of...
6.
Davies J, Hilton L, Jiang A, Barrans S, Burton C, Johnson P, et al.
Blood Adv
. 2023 Aug;
7(20):6156-6162.
PMID: 37595057
No abstract available.
7.
Davies A, Barrans S, Stanton L, Caddy J, Wilding S, Saunders G, et al.
J Clin Oncol
. 2023 Mar;
41(15):2718-2723.
PMID: 36972491
JCO The REMoDL-B phase III adaptive trial compared rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) versus R-CHOP + bortezomib (RB-CHOP) in patients with diffuse large B-cell lymphoma (DLBCL), stratified by...
8.
Brownlie R, Kennedy R, Wilson E, Milanovic M, Taylor C, Wang D, et al.
Blood Adv
. 2023 Mar;
7(15):3874-3890.
PMID: 36867577
Multiple myeloma (MM) shows constitutive activation of canonical and noncanonical nuclear factor κB (NF-κB) signaling via genetic mutations or tumor microenvironment (TME) stimulations. A subset of MM cell lines showed...
9.
Miles J, Townend S, Milonaityte D, Smith W, Hodge F, Westhead D, et al.
PLoS Biol
. 2023 Feb;
21(2):e3001605.
PMID: 36780563
Organismal proteostasis is maintained by intercellular signaling processes including cell nonautonomous stress responses such as transcellular chaperone signaling (TCS). When TCS is activated upon tissue-specific knockdown of hsp-90 in the...
10.
Bewicke-Copley F, Korfi K, Araf S, Hodkinson B, Kumar E, Cummin T, et al.
Blood Adv
. 2022 Aug;
7(5):845-855.
PMID: 35947123
Despite the effectiveness of immuno-chemotherapy, 40% of patients with diffuse large B-cell lymphoma (DLBCL) experience relapse or refractory disease. Longitudinal studies have previously focused on the mutational landscape of relapse...